Verekitug (UPB-101)
Sponsors
Upstream Bio Inc.
Conditions
Chronic Rhinosinusitis With Nasal PolypsChronic Rhinosinusitis with Nasal PolypsModerate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)Severe Asthma
Phase 2
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
CompletedNCT06164704
Start: 2023-12-18End: 2025-07-22Updated: 2026-09-18
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
CompletedNCT06196879
Start: 2024-02-27End: 2026-03-19Updated: 2026-05-01
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Efficacy and Safety of Verekitug (UPB-101) in Participants with Chronic Rhinosinusitis with Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
CompletedCTIS2023-508231-31-00
Start: 2024-07-24End: 2025-07-11Target: 45Updated: 2025-07-01
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-ranging Study to Evaluate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants with Severe Asthma (VALIANT)
Active, not recruitingCTIS2023-507410-27-00
Start: 2024-06-19Target: 182Updated: 2025-09-29
A Long-Term Extension Study to Evaluate Safety and Efficacy of Verekitug (UPB-101) in Adult Participants with Severe Asthma who Completed the VALIANT Trial
RecruitingCTIS2024-519469-23-00
Start: 2025-10-20Target: 123Updated: 2026-01-26
A Phase 2b Randomized, Double-blind, Placebo-controlled, Parallel-Group Study to Assess Efficacy and Safety of Verekitug (UPB-101) in Participants with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
RecruitingCTIS2025-520488-42-00
Start: 2025-09-17Target: 287Updated: 2025-09-15